Esophageal cancer is a disease with disappointing prognosis. Currently, there are no predictive factors that can identify patients who on the one hand would likely benefit from tri-modality management and, on the other hand, would not be significantly affected by the morbidity accompanying the treatment. MicroRNAs are short non-coding RNAs responsible for post-transcriptional modification of gene expression by binding to 3'-UTR of messenger RNA and represent emerging potential predictive biomarkers of treatment (chemotherapy and radiotherapy) efficacy and toxicity. We reviewed the current literature, addressing the potential predictive role of microRNAs for efficacy of chemotherapy (specifically cisplatin, 5-fluorouracil, doxorubicin and paclitaxel) and radiotherapy, including predicted targets in the cell. Altogether 82 articles were identified and included in this review. This may be the first review on this topic specifically focusing on neoadjuvant treatment of esophageal cancer.

Department of Oncology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Surgery Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University University Hospital in Olomouc Olomouc Czech Republic

Toxicogenomics Unit National Institute of Public Health Prague Czech Republic

Citace poskytuje Crossref.org

From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer